# Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

> **NCT06011798** · PHASE2 · COMPLETED · sponsor: **Unity Biotechnology, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Diabetic Macular Edema
- Retinal Disease
- Macular Edema
- Diabetes Mellitus
- Diabetic Retinopathy
- Retinal Degeneration
- Retinal Diseases
- Eye Diseases
- Edema

## Interventions

- **DRUG:** Aflibercept
- **DRUG:** foselutoclax

## Key facts

- **NCT ID:** NCT06011798
- **Lead sponsor:** Unity Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-23
- **Primary completion:** 2025-01-21
- **Final completion:** 2025-04-08
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06011798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06011798, "Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06011798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*